Research programme - ROR gamma t inhibitors - Orca Pharmaceuticals/AstraZeneca

Drug Profile

Research programme - ROR gamma t inhibitors - Orca Pharmaceuticals/AstraZeneca

Alternative Names: ROR inhibitors - Orca Pharmaceuticals/AstraZeneca; RORγt inhibitors - Orca Pharmaceuticals/AstraZeneca

Latest Information Update: 03 Mar 2015

Price : $50

At a glance

  • Originator Orca Pharmaceuticals
  • Developer AstraZeneca; Orca Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 25 Feb 2015 Orca Pharmaceuticals collaborates with AstraZeneca for the development of ROR gamma antagonists
  • 25 Feb 2015 Early research in Autoimmune disorders in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top